SpyGlass Pharma Completes Enrollment for Phase 1/2 Clinical Trial

SpyGlass Pharma, a private biotechnology company specializing in ophthalmology, has announced the completion of enrollment for its Phase 1/2 multi-center, randomized clinical trial. This marks a significant step in evaluating its innovative drug delivery platform for patients with glaucoma or ocular hypertension.

Advancing Glaucoma Treatment

“Completing enrollment in this study is an important milestone in our efforts to bring the SpyGlass technology to millions of patients around the world,” said Patrick Mooney, Chief Executive Officer of SpyGlass Pharma.

The company is working closely with the FDA as it prepares to advance the platform into two large Phase 3 trials, which will further evaluate the platform's safety and efficacy.

Innovative Drug Delivery Platform

SpyGlass Pharma has developed a groundbreaking intraocular lens-mounted controlled drug delivery platform. Key features include:

       • Drug of Choice: Delivers bimatoprost, a widely used prostaglandin analog for lowering intraocular pressure.

       • Long-Lasting Effect: Provides sustained drug delivery to targeted tissues for up to three years.

       • Ease of Use: Can be implanted during routine cataract surgery, making it a seamless addition to standard surgical procedures.

A Game-Changer for Glaucoma Management

“As the SpyGlass platform is implanted using standard surgical techniques, it could significantly expand the integration of glaucoma treatment into routine cataract procedures,” said Malik Kahook, MD, co-founder of SpyGlass Pharma.

This approach offers several potential advantages:

       • Broader adoption across a wide range of surgeons and practices.

       • Enhanced convenience for both patients and providers.

       • A step forward from traditional glaucoma interventions.

Looking Ahead

The completion of this Phase 1/2 trial represents a key milestone as SpyGlass Pharma aims to revolutionize the treatment landscape for glaucoma and ocular hypertension. The company’s innovative platform could pave the way for combining glaucoma management with routine cataract procedures, ultimately transforming patient care.